However, patient adherence rates across all patients and their relatives indicate that identifying P/LP variants in ATM, CHEK2, PALB2, and other DDR genes associated with increased risk of breast and ovarian cancer also impact patient care. This evidence concerns the gene PALB2 and ovarian carcinoma.